On the morning of July 22nd, a meeting was held at the 6th-floor auditorium of 10A Quang Trung Office, Ha Dong, between the BOD of ASKA Pharmaceutical Holdings Company (Japan) and key personnel of HATAPHAR.
Attending the conference from ASKA were: Mr. Sohta Yamaguchi – Board Member, CEO of ASKA; Mr. Hiroyasu Nishioka – Board Member of ASKA, Board Member of HATAPHAR; and Mr. Keisuke Oshio – Head of International Business Department, ASKA, Board Member of HATAPHAR. From Hataphar, the Board of Directors and all key management personnel of the company participated.
To kick off the program, the conference featured an impressive introduction to ASKA Pharmaceutical Holdings Company. With over a century of development since 1920, ASKA has solidified its position as one of the top 20 pharmaceutical companies in Japan. The presentation delved into ASKA’s business philosophy, “Contributing to human health and the advancement of pharmaceutical science,” and highlighted its core strengths in internal medicine, obstetrics/gynecology, and urology. Breakthrough achievements in research and development, along with a strong presence in both domestic and international markets, underscored ASKA’s capabilities and reputation.
Following this, representatives from Hataphar’s leadership provided a detailed presentation on the company’s medium and long-term strategic vision. To become one of Vietnam’s leading pharmaceutical companies, Hataphar is focusing on key development directions: modernizing production, developing high-quality products, expanding its distribution system, and strengthening its brand position.
The core of the conference was an open and constructive discussion, where the leadership from both sides emphasized their commitment to a deep and comprehensive cooperative relationship. Both ASKA and Hataphar leadership shared the understanding that this collaboration would create tremendous synergy. This synergy comes from combining ASKA’s international management experience, advanced production technology, and superior R&D capabilities with Hataphar’s deep understanding of the domestic market, solid production foundation, and extensive distribution network. This forms a strong foundation for both companies to jointly research, develop, produce, and introduce high-quality, safe, and effective pharmaceutical products to the Vietnamese market, best serving community healthcare and protection.
The meeting between ASKA and Hataphar concluded successfully. This event marks a significant milestone, further strengthening the strategic partnership and fostering mutual trust and understanding.
